secwatch.observer — SEC 8-K summary
======================================

Issuer:     CITIUS ONCOLOGY, INC. (CTOR)
CIK:        0001851484
Form:       8-K
Filed at:   2022-10-19T23:59:59+00:00
Accession:  0001493152-22-028873
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 3.02, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TenX Keane Acquisition closes $66M IPO; $67.3M placed in trust for business combination
--------------------------------------------------------------------------------

- IPO of 6,600,000 units at $10/unit (including 600,000 over-allotment units) for gross proceeds of $66,000,000.
- Private placement of 394,000 placement units to sponsor at $10/unit, raising additional $3,940,000.
- Total $67,320,000 deposited into trust account for the benefit of public shareholders.
- Units trade on Nasdaq as TENKU; shares as TENK; rights as TENKR.
- Maxim Group LLC acted as sole book-running manager; IPO closed October 18, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1851484/000149315222028873/0001493152-22-028873-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1851484/000149315222028873/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-028873

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer